NCT04593654View on ClinicalTrials.gov

Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients

CompletedOBSERVATIONAL
Enrollment

257

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

August 15, 2020

Study Completion Date

October 15, 2020

Conditions
Covid19Thromboembolism
Interventions
DRUG

Dose of tinzaparin or dalteparin

The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Trial Locations (1)

11883

Södersjukhuset, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT04593654 - Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients | Biotech Hunter | Biotech Hunter